Lead: Since September, the Trump administration struck agreements with 16 major pharmaceutical companies intended to secure lower prices for some Americans. On Sept. 30 Pfizer’s chief executive joined the White House announcement; the full terms of the deals have not been released. Despite those pacts, pharmaceutical companies raised list prices on a wide set of products in January 2026, including drugs for cancer, heart failure and diabetes. The market response — a median list-price rise of 4% — has complicated the administration’s claims of immediate consumer relief.
Key Takeaways
- Sixteen drugmakers signed deals with the administration beginning in September; the agreements include commitments on Medicaid discounts and other pricing pledges.
- In the first two weeks of January 2026, companies increased list prices on 872 brand-name drugs, according to analysis by 46brooklyn.
- The median list-price increase was 4%, matching the prior year’s January pattern for brand-name drugs.
- Pfizer raised prices on 72 products in January, including a 15% list-price increase on a COVID‑19 vaccine.
- Merck increased prices on 18 products, among them Isentress (HIV) and Belsomra (insomnia).
- There were 18 notable list-price reductions in early January, including a 75% commercial-market cut for the insulin product Fiasp.
- Medicare drug-price negotiations reduced Medicare prices for 10 selected drugs by 38%–79%, with those discounts taking effect in January 2026.
Background
The administration announced individually negotiated agreements with 16 pharmaceutical firms starting in September, framing them as a way to lower U.S. prices and push other wealthy nations toward paying more for new medicines. Officials described elements such as expanded Medicaid discounts, parity for launch prices across wealthy countries and discounts for cash-paying patients via a new portal. However, the deal documents themselves have not been published, leaving key terms and their scope opaque.
U.S. drug pricing rests on list prices as a visible benchmark even though insurers, pharmacy benefit managers (PBMs) and manufacturers typically transact at net prices after rebates and discounts. Advocates of the administration’s approach argue that visible commitments and new cash-payer discounts can provide relief for uninsured patients. Critics and many health-policy experts note that list-price changes do not automatically translate into lower out‑of‑pocket costs for most insured Americans, since insurer formularies, PBM contracting and Medicaid rules remain central to what patients actually pay.
Main Event
January is the traditional month when manufacturers adjust list prices for the year ahead, and in 2026 that pattern continued despite the administration’s headline agreements. Data compiled by 46brooklyn show 872 brand-name drugs experienced list-price increases in the first half of January 2026. Those increases spanned therapeutic classes, including oncology agents, heart-failure medicines and type 2 diabetes therapies.
Pfizer, the first company to announce a deal at a Sept. 30 White House event, raised the list price on 72 of its products in January, the analysis found. Among those changes was a reported 15% rise in the list price for one of Pfizer’s COVID vaccines. Pfizer told reporters these list increases were modest and reflected investment needs, and the company emphasized that net prices after rebates and discounts have fallen.
Merck reported list-price hikes on 18 products, including the HIV drug Isentress and the insomnia medication Belsomra. Merck described its adjustments as reflecting clinical value and said the specific terms of its administration agreement are confidential while the firm works toward what it called fairer global pricing. At the same time, several companies implemented large cuts on particular products in the commercial market — illustrating divergent commercial strategies across the sector.
Analysis & Implications
The simultaneous presence of publicized deals and continued list-price increases highlights a gap between headline commitments and broad market behavior. List prices remain a public reference point that can influence coverage decisions and patient cost sharing; a 4% median list-price increase is meaningful for insurers and for patients in high-deductible plans who pay coinsurance based on list price. Even if net prices to insurers fall, visible list increases can shift which drugs appear cost‑effective on formularies and can raise patient out‑of‑pocket exposure.
Policy advocates point to targeted discounts in the deals — Medicaid enhancements and cash-payer reductions — as useful, particularly for uninsured patients. Yet most Americans obtain drugs through employer-sponsored or other private insurance where PBM contracts and manufacturer rebates largely determine net costs. Because the deal text remains confidential, it is difficult to judge how much broader consumer impact the agreements will produce beyond those specific populations explicitly mentioned.
Medicare’s negotiated price reductions for 10 drugs (38%–79%) that took effect in January 2026 offer a separate lever for lowering costs. Some manufacturers reacted by reducing commercial list prices sharply for certain products, such as a 75% cut for Fiasp in the commercial market. That suggests government negotiation can influence broader pricing strategies — but the effect is uneven, with some negotiated drugs showing no change or even list-price increases outside Medicare.
Comparison & Data
| Category | Count | Median List-Price Change |
|---|---|---|
| Companies signing administration deals | 16 firms | N/A |
| Brand-name drugs with price hikes (early Jan 2026) | 872 drugs | +4% |
| Pfizer products with price increases (Jan 2026) | 72 products | Varies; includes a 15% COVID shot increase |
| Commercial list-price cuts (early Jan) | 18 cuts | Examples: Fiasp −75%; others −37% to −44% |
The table above summarizes public counts and median changes from the 46brooklyn analysis and company statements. It shows the contrast between widespread modest list‑price increases and a smaller set of pronounced commercial cuts tied to competitive and policy pressures, including Medicare negotiation results.
Reactions & Quotes
Advocates who track list prices say market activity after the deals offers a clear reality check. 46brooklyn’s leadership points to January as the pivotal month for list-price resets and sees the observed pattern as consistent with past years.
“The real truth serum is what’s happening in the marketplace after those deals occur; January is prime time for list-price changes on brand-name drugs.”
Antonio Ciaccia, CEO, 46brooklyn (research nonprofit)
The White House described its view that the transactional discounts embedded in the confidential agreements — and forthcoming legislative proposals — are what matter most for patients, not headline list prices.
“List prices do not capture the targeted discounts going to state Medicaid programs and to patients who pay cash; legislative steps will codify those protections.”
Kush Desai, White House spokesperson (official statement)
Health policy researchers caution against attributing price moves to any single cause, noting a mix of market, regulatory and competitive drivers.
“It’s difficult to pin any single drug or situation on one policy; these decisions are usually the product of multiple factors.”
Dr. Ben Rome, health policy researcher, Brigham and Women’s Hospital (academic)
Unconfirmed
- The full, binding terms of the 16 individual agreements have not been published; how broadly discounts apply beyond Medicaid and selected cash-payer programs is unknown.
- Whether the January list‑price increases constitute a breach of any confidential commitments cannot be verified without access to the deal documents.
- The extent to which net prices paid by private insurers fell or rose in 2026 compared with 2025 is not publicly available in comprehensive, consolidated data.
Bottom Line
The administration’s public deals with 16 drugmakers produced high-profile statements about discounts for particular programs and parity ambitions, but January 2026 list-price activity shows continued complexity in U.S. drug pricing. A median 4% list-price rise and hundreds of individual increases underline that headline agreements do not automatically translate into broad-based, immediate list‑price relief for most insured Americans.
Policy levers such as Medicare negotiation appear to have exerted measurable pressure in some cases, prompting deep commercial cuts for certain products; yet effects are uneven across drugs and payers. For consumers and policymakers, the key questions remain: what exactly the confidential deals commit to, how rebates and net prices evolve for commercially insured patients, and whether forthcoming legislation will translate negotiated or promised discounts into tangible, system-wide savings.
Sources
- NPR — news report summarizing 46brooklyn analysis and official statements (media)
- 46brooklyn — nonprofit drug-price research organization cited for January 2026 analysis (research nonprofit)
- Pfizer — company statements about pricing and net-price dynamics (company)
- Merck — corporate communications regarding price adjustments and global pricing work (company)
- Centers for Medicare & Medicaid Services (CMS) — materials on Medicare drug-price negotiation and implementation (official government)